Mini-review uncovers preclinical efficacy and synthesis details of drug delivery nanomaterials for endometrial cancer, highlighting their therapeutic potential.
Endometrial cancer, accounting for over 90% of uterine malignancies, has experienced a significant global rise in incidence and mortality. Conventional therapies face limitations including fertility compromise, systemic toxicity, drug resistance, and poor outcomes in advanced/recurrent cases. Considering the unique physical and chemical properties of nanomaterials, the emerging drug delivery approaches based on nanomaterials are regarded as a promising pathway for enhanced therapeutic efficiency to combat endometrial cancer. Herein, this mini-review discusses emerging drug delivery approaches to overcome current treatment challenges. We classify common therapeutic nanomaterials into polymer-based nanocarriers, quantum dots, liposomes, and exosomes, analyzing their synthesis, mechanisms, and preclinical efficacy. Finally, scientific challenges and future perspectives for ongoing research in this field are presented.
No takes yet. Share an insight, caveat, or question.
Ping Jin (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: